Toggle light / dark theme

A potassium-gated ion channel identified!

Potassium ions (K⁺) are essential for all cells and living organisms. Scientists have long believed that K⁺ merely passes through ion channels and transporters, rather than acting as an extracellular ligand or molecular “switch.” Indeed, there had been no clear evidence that K⁺ functions as a ligand for membrane proteins in animals or plants—until now.

“Unexpectedly, we made this discovery serendipitously while testing the effect of aspartic acid, with K⁺ added as a counter cation, on Alka, an ion channel located in the brain of Drosophila melanogaster,” said the author. “The compound was effective. At first, we thought the effect was due to aspartic acid, but we ultimately realized that it was caused by K⁺, meaning that Alka functions as a membrane receptor that detects extracellular K⁺ as a ligand.”

Ion channel currents in Alka-expressing cells changed significantly in response to K⁺ levels. The researchers combined electrophysiological analysis with AlphaFold3, an AI-based protein structure prediction tool. This allowed them to identify the K⁺-binding site in Alka. This site creates a chemical environment favorable for K⁺, similar to that found in aqueous solution or in the well-known selectivity filter of K⁺ channels.

Closing the gap between animal movement and robotic control

Animals move with a level of precision and adaptability that robots struggle to match. In Carnegie Mellon University’s Department of Mechanical Engineering, researchers are developing a new AI-driven approach to uncover how brains and bodies work together. By turning complex biological systems into models that can be tested and refined, the team seeks to understand and replicate animal performance in robotic systems.

One focus of The Biohybrid and Organic Robotics Lab are neuromechanical models that simulate how neural signals and physical movement continuously inform one another. These models are powerful, but difficult to build because, with countless parameters, even the smallest miscalculation can lead to large gaps between simulated behavior and what researchers observe in real animals.

“Biological systems are incredibly complex,” said Camila Fernandez, Ph.D. Candidate in the department of mechanical engineering. “We’re trying to model something where everything affects everything, and it’s not always clear which piece we need to adjust when outcomes don’t match predictions.”

Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations

Abeliovich et al. make a compelling case for the promise of using gene therapy to treat Parkinson’s disease (PD) patients who possess mutations in the GBA1 gene. People interested in the clinical-translational side of biomedicine should definitely check this out!


This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno continues to develop impressive new AAV capsids with their AI-guided design approach!


About Dyno Therapeutics.

Dyno Therapeutics is on a mission to build high-performance genetic technologies that transform patients’ lives. Dyno applies AI to build technologies for gene delivery and sequence design that advance “Genetic Agency” — an individual’s ability to take action at the genetic level to live a healthier life — through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications including eye, muscle and CNS. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including through strategic collaborations with leading gene therapy developers Astellas and Roche and with technology companies including NVIDIA. Dyno’s AI-designed capsids are available for direct licensing and through the Dyno Frontiers Network. Visit www.dynotx.com for more information.

‘Dyno Therapeutics’, ‘dyno’, the Dyno logo, and mountain logo are registered trademarks of Dyno Therapeutics, Inc. All rights reserved.

/* */